Quick Answer
Theravance Biopharma, Inc. reported Research And Development Expense of $37.41 million for the year ending 2025.
- Theravance Biopharma, Inc. showed a decrease of -0.6% in Research And Development Expense from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Theravance Biopharma, Inc.'s Research And Development Expense has declined by 67.2%.
- Historical annual values: Fiscal year 2025: $37.41 million | Fiscal year 2024: $37.64 million | Fiscal year 2023: $40.62 million | Fiscal year 2022: $63.39 million | Fiscal year 2021: $193.66 million | Fiscal year 2020: $260.95 million | Fiscal year 2019: $219.25 million | Fiscal year 2018: $201.35 million | Fiscal year 2017: $173.89 million | Fiscal year 2016: $141.71 million | Fiscal year 2015: $129.17 million | Fiscal year 2014: $168.52 million | Fiscal year 2013: $120.58 million | Fiscal year 2012: $114.00 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: